BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alaverdashvili M, Laprairie RB. The future of type 1 cannabinoid receptor allosteric ligands. Drug Metab Rev 2018;50:14-25. [PMID: 29355038 DOI: 10.1080/03602532.2018.1428341] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Mcelroy DL, Roebuck AJ, Greba Q, Garai S, Brandt AL, Yilmaz O, Cain SM, Snutch TP, Thakur GA, Laprairie RB, Howland JG. The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. IBRO Neuroscience Reports 2022. [DOI: 10.1016/j.ibneur.2022.01.006] [Reference Citation Analysis]
2 Gado F, Ceni C, Ferrisi R, Sbrana G, Stevenson LA, Macchia M, Pertwee RG, Bertini S, Manera C, Ortore G. CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n‑butyl‑diphenylcarboxamides as allosteric modulators. Eur J Pharm Sci 2021;169:106088. [PMID: 34863873 DOI: 10.1016/j.ejps.2021.106088] [Reference Citation Analysis]
3 Jakowiecki J, Abel R, Orzeł U, Pasznik P, Preissner R, Filipek S. Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling. Molecules 2021;26:2456. [PMID: 33922473 DOI: 10.3390/molecules26092456] [Reference Citation Analysis]
4 Aderibigbe AO, Pandey P, Doerksen RJ. Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569. J Biomol Struct Dyn 2021;:1-19. [PMID: 33480332 DOI: 10.1080/07391102.2021.1873187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gado F, Mohamed KA, Meini S, Ferrisi R, Bertini S, Digiacomo M, D'Andrea F, Stevenson LA, Laprairie RB, Pertwee RG, Manera C. Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor. Eur J Med Chem 2021;211:113116. [PMID: 33360803 DOI: 10.1016/j.ejmech.2020.113116] [Reference Citation Analysis]
6 Mielnik CA, Sugamori KS, Finlay DB, Thorpe HHA, Schapira M, Sivananthan N, Li CK, Lam VM, Harrington S, Abdelrahman MH, Trembleau LA, McIntyre Burnham W, Khokhar JY, Salahpour A, Ramsey AJ, Glass M, Greig IR, Ross RA. A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models. Neuropsychopharmacology 2021;46:413-22. [PMID: 33036015 DOI: 10.1038/s41386-020-00876-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Datta U, Kelley LK, Middleton JW, Gilpin NW. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats. Psychopharmacology (Berl) 2020;237:3729-39. [PMID: 32857187 DOI: 10.1007/s00213-020-05650-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Gado F, Meini S, Bertini S, Digiacomo M, Macchia M, Manera C. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery. Future Med Chem 2019;11:2019-37. [PMID: 31517528 DOI: 10.4155/fmc-2019-0005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
9 Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG. Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Front Mol Neurosci 2020;13:54. [PMID: 32410959 DOI: 10.3389/fnmol.2020.00054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
10 Morales P, Jagerovic N. Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opin Drug Discov 2020;15:917-30. [PMID: 32336154 DOI: 10.1080/17460441.2020.1752178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
11 Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB1R antagonists. Pharmacology & Therapeutics 2020;208:107477. [DOI: 10.1016/j.pharmthera.2020.107477] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
12 Bruder M, Polo G, Trivella DBB. Natural allosteric modulators and their biological targets: molecular signatures and mechanisms. Nat Prod Rep 2020;37:488-514. [PMID: 32048675 DOI: 10.1039/c9np00064j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Thapa D, Cairns EA, Szczesniak AM, Kulkarni PM, Straiker AJ, Thakur GA, Kelly MEM. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. Molecules 2020;25:E417. [PMID: 31968549 DOI: 10.3390/molecules25020417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
14 Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, Thakur GA. Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem 2020;63:542-68. [PMID: 31756109 DOI: 10.1021/acs.jmedchem.9b01142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
15 Hryhorowicz S, Kaczmarek-Ryś M, Andrzejewska A, Staszak K, Hryhorowicz M, Korcz A, Słomski R. Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. Int J Mol Sci 2019;20:E5874. [PMID: 31771126 DOI: 10.3390/ijms20235874] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
16 Tseng CC, Baillie G, Donvito G, Mustafa MA, Juola SE, Zanato C, Massarenti C, Dall'Angelo S, Harrison WTA, Lichtman AH, Ross RA, Zanda M, Greig IR. The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB1 Receptor Positive Allosteric Modulators. J Med Chem 2019;62:5049-62. [PMID: 31050898 DOI: 10.1021/acs.jmedchem.9b00252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
17 Coughlin Q, Hopper AT, Blanco MJ, Tirunagaru V, Robichaud AJ, Doller D. Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases. J Med Chem 2019;62:5979-6002. [PMID: 30721063 DOI: 10.1021/acs.jmedchem.8b01651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
18 Pandey P, Roy KK, Doerksen RJ. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist. J Biomol Struct Dyn 2020;38:32-47. [PMID: 30652534 DOI: 10.1080/07391102.2019.1567384] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
19 Lafreniere JD, Kelly MEM. Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options. Neuronal Signal 2018;2:NS20170144. [PMID: 32714590 DOI: 10.1042/NS20170144] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
20 Horn H, Böhme B, Dietrich L, Koch M. Endocannabinoids in Body Weight Control. Pharmaceuticals (Basel) 2018;11:E55. [PMID: 29849009 DOI: 10.3390/ph11020055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]